UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO.          | FILING DATE                         | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--------------------------|-------------------------------------|----------------------|---------------------|------------------|
| 10/502,420               | 08/26/2005                          | Richard O Chen       | 27763-705.831       | 5778             |
|                          | 7590 10/02/200<br>SINI GOODRICH & F | EXAMINER             |                     |                  |
| 650 PAGE MILL ROAD       |                                     |                      | CLOW, LORI A        |                  |
| PALO ALTO, CA 94304-1050 |                                     | ART UNIT             | PAPER NUMBER        |                  |
|                          |                                     | 1631                 |                     |                  |
|                          |                                     |                      |                     |                  |
|                          |                                     |                      | MAIL DATE           | DELIVERY MODE    |
|                          |                                     |                      | 10/02/2008          | PAPER            |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

|  | Application No.  | Applicant(s)           |  |  |  |  |
|--|--|------------------------|--|--|--|--|
|  | 10/502,420   | CHEN ET AL.            |  |  |  |  |
| Office Action Summary  | Examiner   | Art Unit               |  |  |  |  |
|  | LORI A. CLOW   | 1631                   |  |  |  |  |
| The MAILING DATE of this communication ap<br>Period for Reply  | opears on the cover sheet with the   | correspondence address |  |  |  |  |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). |  |                        |  |  |  |  |
| Status   |  |                        |  |  |  |  |
| <ol> <li>Responsive to communication(s) filed on <u>23 July 2004</u>.</li> <li>This action is <b>FINAL</b>. 2b) This action is non-final.</li> <li>Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i>, 1935 C.D. 11, 453 O.G. 213.</li> </ol>   |  |                        |  |  |  |  |
| Disposition of Claims  |  |                        |  |  |  |  |
| <ul> <li>4)  Claim(s) 1-53 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdrawn from consideration.</li> <li>5)  Claim(s) is/are allowed.</li> <li>6)  Claim(s) is/are rejected.</li> <li>7)  Claim(s) is/are objected to.</li> <li>8)  Claim(s) 1-53 are subject to restriction and/or election requirement.</li> </ul>   |  |                        |  |  |  |  |
| Application Papers   |  |                        |  |  |  |  |
| <ul> <li>9) The specification is objected to by the Examiner.</li> <li>10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).</li> <li>11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.</li> </ul>  |  |                        |  |  |  |  |
| Priority under 35 U.S.C. § 119   |  |                        |  |  |  |  |
| <ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>   |  |                        |  |  |  |  |
| Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date   | 4)  Interview Summary Paper No(s)/Mail D 5)  Notice of Informal I 6)  Other: | oate                   |  |  |  |  |

## **DETAILED ACTION**

## **Election/Restrictions**

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-25 and 49, drawn to a method for identifying a drug discovery target.

Group II, claim(s) 26-44, drawn to a method for evaluating user-supplied genomics data using a structured database that permits the computations of complex relationships.

Group III, claim(s) 45, drawn to a method for identifying a new use for a known therapy comprising the steps of providing a means for storing and accessing genomics information.

Group IV, claim(s) 46, drawn to a method for prioritizing candidate development compounds.

Group V, claim(s) 47, drawn to a method for identifying disease-related pathways.

Group VI, claim(s) 48, drawn to a method for identifying and validating a genotypic marker for a disease state.

Group VII, claim(s) 50, drawn to a method of conducting business that comprises receiving compensation from a customer.

Group VIII, claim(s) 51, drawn to a drug discovery target.

Group IX, claim(s) 52, drawn to a method of drug discovery.

Group X, claim(s) 53, drawn to a drug candidate.

The inventions listed as Groups I-X do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The methods of Group I-VII and IX all require

Art Unit: 1631

different method steps to achieve different stated outcomes and therefore so not share the same inventive concept or special technical feature. For example, the method of Group I is drawn to a method for identifying a drug discovery target comprising steps of storing and accessing genomic information and querying a database to identify disease-related pathways and identifying interactions and actor concepts. Whereas, the method of Group II is drawn to a method of evaluating user-supplied genomics data comprising the very different steps of defining a profile model, building a collection of profiles, identifying overlapping data and analyzing statistically significant profiles.

The products of Groups VIII and X are not formed by the same inventive concept and therefore do not share the same special technical feature. Further, the features of method claim 1 reside in identifying a drug discovery candidate by querying a database and the technical feature of claim 52 resides in identifying a drug discovery candidate by querying a computer system to identify a disease pathway and screening compounds. Neither the same nor a corresponding special technical feature is present in any of the targets of claim 51 or 53. No manufacturing relationship exists between the screening method and the claimed targets nor is the screening method a method of using the claimed targets. Therefore, there is not single general concept that links the methods to the claimed targets and unity of invention is lacking.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

Application/Control Number: 10/502,420 Page 4

Art Unit: 1631

currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## **Inquiries**

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993) (See 37 CFR § 1.6(d)). The Central Fax Center Number is (571) 273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lori A. Clow, Ph.D., whose telephone number is (571) 272-0715. The examiner can normally be reached on Monday-Friday from 10 am to 6:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marjorie Moran can be reached on (571) 272-0720.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

October 2, 2008 /Lori A. Clow, Ph.D./ Art Unit 1631 Application/Control Number: 10/502,420

Art Unit: 1631

Page 5

Application Number

|            | Application/Control No. | Applicant(s)/Pate<br>Reexamination | ent under |  |
|------------|-------------------------|------------------------------------|-----------|--|
| 10/502,420 |                         | CHEN ET AL.                        |           |  |
|            | Examiner                | Art Unit                           |           |  |
|            | LODIA CLOW              | 1631                               |           |  |